News & Events
June 18, 2016
Critical Path for Parkinson’s (CPP) members met on June 18th in Berlin for the First Annual Consortium Member MeetingCritical Path for Parkinson’s (CPP) members met on June 18th in Berlin for the First Annual Consortium Member Meeting. A group of 34 world leading experts from industry, academia and patient advocacy organizations convened for a day to discuss the progress to date and the future scope of the multinational consortium. Themes included recognition of......
January 30, 2016
Partners in Parkinson’sJim Grossman, Carl Ames and Jerry Stuzman at the Partners in Parkinson’s Event, Jan 30, 2016, Phoenix, AZ. Over 1500 people came out for this event sponsored by the Michael J. Fox Foundation for Parkinson’s Research, AbbVie, Davis Phinney Foundation, and more to share insights, new exciting research and meet others living with PD. Jerry and Carl......
November 21, 2015
El Tour de Tucson, 2015C-Path cycling team rides annually in the El Tour de Tucson bicycling event along with Carl Ames, PD advocate, cyclist and friend of C-Path. Carl won the buddy hero award at the Davis Phinney Victory Summit in 2013 for his role in helping the most number of people living with PD....
October 20, 2015
Parkinson’s UK Receives CAMD Nonprofit Organization AwardDr. Arthur Roach, Director of Research at Parkinson’s UK accepts the first Nonprofit Organization Award from CAMD presented by Dr. Diane Stephenson, Critical Path Institute, at the annual meeting held at FDA on Oct 20th, 2015. Parkinson’s UK is recognized for their leadership in supporting the launch of a fully dedicated consortium aimed at integrating......
October 7, 2015
PD Imaging Biomarker Team at European Medicines Agency (EMA)Experts of the Parkinson’s disease imaging biomarker team participated in a Scientific Advice meeting at the European Medicines Agency on October 7th 2015. The purpose of this meeting was to review the evidence provided to the Agency that supports the use of Molecular Imaging of the Dopamine Transporter as an enrichment biomarker in clinical trials......